Want to see GB:IDHC full AI Analyst Report?
Top Page
Integrated Diagnostics Holdings
(LSE:IDHC)
Select Model
Select Model
Rating:71Outperform
Price Target:
$0.60
▲(8.55% Upside)
Action:Reiterated
Date:09/15/26
The score is driven primarily by solid financial fundamentals (strong growth and healthy margins, with some debt and cash-conversion risks) and supportive earnings-call guidance and execution in H1 2026. Valuation is favorable (moderate P/E and high yield), while technical indicators are relatively neutral with limited positive momentum, keeping the overall score in the low-70s.
Positive Factors
Broad-based growth
Strong growth across revenue, testing volumes, and patients indicates expanding demand and deeper utilization of IDH’s diagnostic platform. This supports operating leverage, strengthens the company’s provider and patient reach, and provides a durable base for continued earnings growth.
Negative Factors
Working-capital pressure
Rising receivables and inventory absorb cash even while reported earnings grow, increasing the gap between accounting profit and available funds. Continued working-capital investment could constrain funding flexibility and make cash generation less predictable during the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Broad-based growth
Strong growth across revenue, testing volumes, and patients indicates expanding demand and deeper utilization of IDH’s diagnostic platform. This supports operating leverage, strengthens the company’s provider and patient reach, and provides a durable base for continued earnings growth.
Read all positive factors
Integrated Diagnostics Holdings (IDHC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
$308.10M
Dividend Yield4.81%
Average Volume (3M)115.98K
Price to Earnings (P/E)10.7
Beta (1Y)0.83
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees7,137
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)2.59
Shares Outstanding581,326,300
10 Day Avg. Volume109,822
30 Day Avg. Volume115,984
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)6.10
Price to Sales (P/S)2.63
P/FCF Ratio14.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.73
Revenue Forecast (FY)$9.82B
Integrated Diagnostics Holdings Business Overview & Revenue Model
Company Description
Integrated Diagnostics Holdings plc (IDHC.L) functions as a leading consumer healthcare enterprise, offering a wide array of medical diagnostic services directly to its clientele. The company's comprehensive service catalog features around 2,000 d...
How the Company Makes Money
IDHC makes money primarily by performing diagnostic tests and pathology services for patients referred by healthcare providers and billing for those services. Key revenue streams generally include (1) pathology services, where tissue and other spe...
Integrated Diagnostics Holdings Earnings Call Summary
Earnings Call Date:Sep 11, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 12, 2026
Earnings Call Sentiment Positive
The call was strongly positive overall. Highlights significantly outweighed the lowlights, with 37% revenue growth, record testing volume, expanding margins, 47% net profit growth, improved Nigeria performance, and rapid Saudi expansion. The main challenges were geopolitical uncertainty, constrained Sudan operations, Saudi Arabia remaining below break-even, higher working capital balances, lower net cash, and the decision not to pay an interim dividend.Positive Updates
Strong Broad-Based First-Half Growth
IDH reported broad-based operational and financial growth in H1 2026, with revenue increasing 37% year-on-year to EGP 4.9 billion. Test volumes rose 20% to 23.6 million, average revenue per test increased 14% to EGP 206, and patients served increased 14% to 4.9 million.
Negative Updates
Geopolitical and Macroeconomic Uncertainty
Management said evolving macroeconomic conditions and regional developments may introduce volatility across parts of the Group's footprint. Egypt's inflation remained sensitive to currency movements and energy-related pressures, the Egyptian Pound experienced renewed pressure earlier in 2026, and management is monitoring potential effects on economic activity, patient volumes, and consumer sentiment.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Broad-Based First-Half Growth
IDH reported broad-based operational and financial growth in H1 2026, with revenue increasing 37% year-on-year to EGP 4.9 billion. Test volumes rose 20% to 23.6 million, average revenue per test increased 14% to EGP 206, and patients served increased 14% to 4.9 million.
Read all positive updates
Company Guidance
For 2026, management is forecasting revenue of EGP 11 billion, gross profit of 46%, EBITDA margin of 37%, and net profit margin of 20%; margins are expected “to have the same margins until the full year of 2026,” with Q3 and Q4 expected “to be resilient” and “a good second half of 2026 with high margins.” Egypt is expected to add “around 50 more branches in H2,” while Saudi Arabia’s plan is to open nine branches this year, with five opened and four to go, and to reach 50 branches in three years; Nigeria is not expected to open more branches, with the focus on increasing revenue, patient footprint, tests, and profitability from existing branches. Management said a 4% price increase implemented during the second quarter “will continue for the rest of the year,” but also said, “We are not planning to do any price increase for the rest of the year,” and confirmed that “for this quarter, there will be no dividend distribution.”Integrated Diagnostics Holdings Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.17B | 7.86B | 5.72B | 4.12B | 3.61B | 5.22B |
| Gross Profit | 3.97B | 3.35B | 2.18B | 1.52B | 1.46B | 2.80B |
| EBITDA | 2.89B | 2.89B | 2.09B | 1.28B | 1.29B | 2.57B |
| Net Income | 1.51B | 1.26B | 1.08B | 510.30M | 541.11M | 1.41B |
Balance Sheet | ||||||
| Total Assets | 9.31B | 8.60B | 7.13B | 5.77B | 5.30B | 6.24B |
| Cash, Cash Equivalents and Short-Term Investments | 1.96B | 2.13B | 1.75B | 860.51M | 815.92M | 2.35B |
| Total Debt | 1.68B | 1.61B | 1.47B | 1.18B | 1.18B | 858.74M |
| Total Liabilities | 4.59B | 4.46B | 3.63B | 2.67B | 2.85B | 3.44B |
| Stockholders Equity | 3.93B | 3.38B | 2.71B | 2.68B | 2.15B | 2.58B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.38B | 1.34B | 217.73M | -100.11M | 2.01B |
| Operating Cash Flow | 0.00 | 1.90B | 1.57B | 543.66M | 208.73M | 2.27B |
| Investing Cash Flow | 0.00 | -552.92M | -446.71M | -243.94M | 990.11M | -1.33B |
| Financing Cash Flow | 0.00 | -851.06M | -749.00M | -330.46M | -1.62B | -647.15M |
Integrated Diagnostics Holdings Technical Analysis
Negative
0.55
Price Trends
0.54
Negative
0.54
Negative
0.58
Negative
Market Momentum
>-0.01
Negative
48.78
Neutral
56.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IDHC, the sentiment is Negative. The current price of 0.55 is above the 20-day moving average (MA) of 0.53, above the 50-day MA of 0.54, and below the 200-day MA of 0.58, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.78 is Neutral, neither overbought nor oversold. The STOCH value of 56.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:IDHC.
Integrated Diagnostics Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | £78.37M | 10.85 | 65.83% | 9.74% | -8.21% | -5.27% | |
71 Outperform | $308.10M | 10.66 | 39.61% | 4.81% | ― | ― | |
62 Neutral | £110.04M | 44.83 | 3.58% | 4.36% | 2.26% | -57.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £26.54M | -12.50 | -55.91% | ― | 40.37% | -13.70% | |
49 Neutral | £20.07M | -1.15 | -1044.57% | ― | 65.60% | 74.84% | |
43 Neutral | £3.33M | -0.57 | -69.62% | ― | -16.27% | -471.21% |
* Healthcare Sector Average
GB:IDHC
Integrated Diagnostics Holdings
0.53
-0.03
-5.53%
GB:BVXP
Bioventix
1,540.00
-718.85
-31.82%
GB:EKF
EKF Diagnostics Holdings
26.00
-4.00
-13.33%
GB:GDR
Genedrive
1.25
0.71
130.20%
GB:CNSL
Omega Diagnostics
1.40
-1.75
-55.56%
GB:ABDX
Abingdon Health PLC
10.50
4.70
81.03%
Integrated Diagnostics Holdings Corporate Events
Business Operations and StrategyDividendsFinancial Disclosures
IDH Delivers Strong H1 Growth as Founders Tighten Control and Cash Is Preserved for Expansion
Positive
Sep 11, 2026
Integrated Diagnostics Holdings reported strong top- and bottom-line growth in the first half of 2026, with revenues rising 37% to EGP 4.9 billion on the back of 20% higher test volumes and a 14% increase in revenue per test. Gross profit climbed ...
Business Operations and StrategyFinancial Disclosures
IDH Schedules Interim 2026 Results and Investor Call
Positive
Sep 4, 2026
Integrated Diagnostics Holdings, a London-listed provider of clinical pathology and radiology services across several Middle Eastern and African markets, plans to publish its unaudited financial results for the second quarter and first half of 202...
Regulatory Filings and Compliance
Integrated Diagnostics Discloses Mandatory Offer Acceptance by CEO-Linked Investor
Neutral
Aug 17, 2026
Integrated Diagnostics Holdings disclosed a transaction involving Hena Holdings Ltd, a person closely associated with chief executive officer Dr Hend El Sherbini. The filing, made under UK Market Abuse Regulation, relates to ordinary shares of $0....
Regulatory Filings and Compliance
Integrated Diagnostics Discloses Major Share Sale by CEO-Linked Entity
Neutral
Aug 4, 2026
Integrated Diagnostics Holdings plc has disclosed a major share transaction involving Hena Holdings Ltd, a legal entity closely associated with Chief Executive Officer Dr. Hend El Sherbini. The notification, made under EU Market Abuse Regulation r...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
IDH Board Rejects CEO-Led Mandatory Offer as Undervaluing Diagnostics Group
Negative
Jul 8, 2026
A mandatory final cash offer at US$0.50 per share has been launched for Integrated Diagnostics Holdings by Hena Holdings, a vehicle wholly owned by IDH’s CEO, Dr Hend El Sherbini, and her mother. The offer document has now been published and...
Other
Insider-Linked Entity Buys $63 Million Stake in Integrated Diagnostics
Positive
Jun 23, 2026
Integrated Diagnostics Holdings plc disclosed a major share transaction involving Hena Holdings Ltd, a company closely associated with CEO Dr. Hend El Sherbini. Hena Holdings purchased 126 million ordinary shares in Integrated Diagnostics from Act...
Executive/Board ChangesM&A TransactionsRegulatory Filings and Compliance
IDH Faces Mandatory Takeover Offer as CEO-Led Vehicle Lifts Stake to 49.6%
Neutral
Jun 23, 2026
Integrated Diagnostics Holdings has entered a new phase of ownership change after Hena Holdings, a vehicle controlled by CEO Dr. Hend El Sherbini and her mother, acquired a 21.67% stake from Actis IDH Limited at USD0.50 per share. This purchase li...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.